LOS ANGELES--(BUSINESS WIRE)--
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq: SVA) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Sinovac Biotech Ltd. shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].
On December 21, 2016, SeekingAlpha.com published an article revealing that according to a recent Beijing court judgment, Weidong Ying, Chairman and CEO of Sinovac, paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, and his wife, in order to assist its vaccine clinical trial and approval.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected].
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161221005925/en/
